STAGE IVB BLADDER CANCER AJCC V8
Clinical trials for STAGE IVB BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVB BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVB BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy plus chemo shows promise against tough cancers
Disease control OngoingThis early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate that have spread. About 15 participants will receive the combinatio…
Matched conditions: STAGE IVB BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
New hope for bladder cancer patients who can't take chemo
Disease control OngoingThis study tests a combination of radiation therapy and two immunotherapy drugs (durvalumab with or without tremelimumab) in people with advanced bladder cancer that cannot be surgically removed or has spread. Participants either cannot have chemotherapy or have chosen not to. Th…
Matched conditions: STAGE IVB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
Can a simple gene test predict who will beat bladder cancer?
Knowledge-focused OngoingThis study looks at whether certain genetic changes in tumors can help doctors know which patients with advanced bladder cancer will benefit from the immunotherapy drug nivolumab. Researchers are testing tumor samples for specific gene mutations and a protein called CXCL13. The g…
Matched conditions: STAGE IVB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:02 UTC